Trial
RTB101 phase 2b dose-finding trial
Research Observatory
Evidence Update
Current evidence
The phase 2b RTB101 trial studied laboratory-confirmed respiratory infections in 652 selected older or comorbid participants across two dose-finding parts, comparing RTB101 regimens with placebo. The first fixed-sequence test of RTB101 plus everolimus failed. A signal for RTB101 10 mg once daily arose in a second prespecified analysis without multiplicity adjustment; this is not confirmatory success.
What changed
The 10-mg signal was from a second prespecified unadjusted analysis; the first fixed-sequence combination test failed.
What did not change
The earlier signal does not override the later phase-3 clinical endpoint null. The registry's old operational label is not a fresh recruiting assertion.
Why it matters
Trial-level detail prevents treating an exploratory signal as a successful confirmatory program.
Main limitation
Dose selection, multiple comparisons and pooled controls; source rounding differences retained.
Next proof
Prospectively powered independent confirmatory trial.
Summary
The phase 2b RTB101 trial enrolled 652 participants across two dose-finding parts.
Intelligence Take
Trial-level detail prevents treating an exploratory signal as a successful confirmatory program.
Limitations
Dose selection, multiple comparisons and pooled controls; source rounding differences retained.